Cite
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
MLA
Susanna, Bianzano, et al. “Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Once-Daily Doses of BI 187004, an Inhibitor of 11 Beta-Hydroxysteroid Dehydrogenase-1, over 28 Days in Patients with Type 2 Diabetes Mellitus and Overweight or Obesity.” Diabetes, ObesitymetabolismREFERENCES, Nov. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........6c7a51a8ecec2f67b90bd7a1f1c10245&authtype=sso&custid=ns315887.
APA
Susanna, B., Matias, N., Leona, P.-M., Barbara, P., & Tim, H. (2022). Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity. Diabetes, ObesitymetabolismREFERENCES.
Chicago
Susanna, Bianzano, Nordaby Matias, Plum-Mörschel Leona, Peil Barbara, and Heise Tim. 2022. “Safety, Tolerability, Pharmacodynamics and Pharmacokinetics Following Once-Daily Doses of BI 187004, an Inhibitor of 11 Beta-Hydroxysteroid Dehydrogenase-1, over 28 Days in Patients with Type 2 Diabetes Mellitus and Overweight or Obesity.” Diabetes, ObesitymetabolismREFERENCES, November. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........6c7a51a8ecec2f67b90bd7a1f1c10245&authtype=sso&custid=ns315887.